They reported that adding a checkpoint inhibitor to chemotherapy in patients with NSCLC progressing on EGFR TKIs does not improve outcomes, and no significant improvement in PFS was reported [105]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.